Biblioteca Inteligente

FDA-cleared application: medicinal leech therapy to relieve venous congestion in compromised tissue flaps awaiting vascular ingrowth.

FDA-cleared application: post-replantation venous decompression in digits, ears, scalp, and partial avulsion injuries.

FDA-cleared application: venous decompression of compromised DIEP, TRAM, and latissimus dorsi flaps in post-mastectomy reconstruction.

Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.

Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.

Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.

Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.

Off-label use with controlled trial evidence for symptomatic improvement in venous claudication, leg heaviness, and edema in CEAP C3-C5 stages.

Off-label adjunct to compression therapy with case-series evidence for accelerated healing in compression-resistant venous ulcers.

Off-label use with case-series evidence for symptomatic relief of leg pain, heaviness, and ulceration in PTS following deep vein thrombosis.

Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.

Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.

Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.

Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.

Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.

Investigational adjunctive use; mechanism includes mild diuresis from blood-volume removal and hirudin-mediated vascular endothelial effects. Not a substitute for pharmacotherapy.

Investigational use for symptomatic relief of varicose tributary discomfort and inflammation; does not eliminate underlying venous reflux.

Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.

Investigational adjunctive use in primary open-angle glaucoma; weak case-series evidence. Not a substitute for IOP-lowering eye drops or surgery.

Investigational use for dry eye disease; mechanism via reduction of meibomian gland inflammation. Weak case-series evidence.

Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.

Investigational adjunctive use; one small pilot suggests transient improvement in tender-point and quality-of-life scores. Not a primary treatment.

Investigational use for non-discogenic sciatica including piriformis syndrome; case-series evidence for pain reduction.

Investigational use for primary Raynaud's phenomenon; mechanism via local vasodilation and rheologic improvement. No RCT evidence.

Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.

Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.

Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.

Investigational use for erythematotelangiectatic rosacea; case-series evidence for reduction in facial erythema.

Investigational use for localized stable plaque psoriasis; small case series suggest plaque thinning. Not a primary treatment.

Investigational use for localized refractory atopic dermatitis; very limited case-series evidence.

Investigational use for stable keloid and hypertrophic scars; case-series evidence for softening and flattening.

Investigational use for chronic recurrent (non-acute) cellulitis with underlying lymphedema or venous insufficiency.

Investigational adjunctive use; case-series evidence for limb-volume reduction when combined with complete decongestive therapy.

Investigational adjunctive use following breast cancer treatment with axillary node dissection; case-series evidence for arm volume reduction.

Investigational use for acute monoarticular gout when NSAIDs and colchicine are contraindicated; small case series.

Investigational use for chronic mid-substance Achilles tendinopathy; case-series evidence for pain and VISA-A score improvement.

Investigational use for non-surgical rotator cuff tendinopathy and chronic shoulder impingement; case-series evidence for pain reduction.

Investigational use for stenosing tenosynovitis of the digital flexor pulleys; small case series.

Investigational use for early-stage Dupuytren's nodules; case-series evidence for nodule softening, not for established contracture.

Investigational use for plantar fascia nodules in early Ledderhose disease; case-series evidence for symptomatic improvement.

Investigational use for stable-phase Peyronie's disease; case-report-level evidence only. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Investigational use for category III CP/CPPS; small case series suggest symptom reduction. Multimodal therapy remains standard.

Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.

Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.

Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.

Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.

Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.

Investigational use for residual symptoms in the post-acute phase of DVT (>6 weeks); contraindicated in acute DVT.

Investigational adjunctive use for Hurley stage I-II hidradenitis suppurativa in quiescent phase between flares.

The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.

Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.

Anti-platelet adhesion protein blocking collagen-mediated platelet activation.

Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.

Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).

RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.

RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.

Direct fibrinogenolytic enzyme — degrades fibrinogen independently of plasmin.

Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.

Factor Xa inhibitor with anti-inflammatory properties.

Hirudin variant from Hirudinaria manillensis with distinct kinetics.

Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.

Inhibitor of TAFI (thrombin-activatable fibrinolysis inhibitor) — synergizes with hirudin's anticoagulant action.

Synthetic 20-amino-acid hirudin analog — FDA-approved direct thrombin inhibitor for PCI anticoagulation ($636M peak revenue).

First-generation recombinant hirudin — FDA-approved 1998 for heparin-induced thrombocytopenia (HIT). Withdrawn 2012 by Bayer for commercial reasons.

Recombinant hirudin variant — FDA-approved 2003 for prophylaxis of DVT after hip replacement surgery.

Oral direct thrombin inhibitor — FDA approved 2010 for stroke prevention in atrial fibrillation. Conceptual descendant of hirudin pharmacology.

Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT and PCI. Designed using hirudin structural insights.

Oral Factor Xa inhibitor — FDA approved 2011. Conceptual descendant of antistasin/leech FXa research.

Oral Factor Xa inhibitor — FDA approved 2012. Part of the DOAC class inspired by leech antistasin discovery.

Oral Factor Xa inhibitor — FDA approved 2015. Latest of the antistasin-inspired DOAC class.

Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Structural inspiration: leech decorsin.

Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.

Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.

Factor Xa inhibitor from Theromyzon tessulatum — Kunitz-domain analog with novel selectivity profile.

Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.

Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.

Platelet GP IIb/IIIa antagonist family member — RGD-motif containing.

Isopeptidase domain of destabilase that cleaves cross-linked fibrin — distinct from lysozyme domain.

ADP-degrading enzyme — prevents platelet aggregation by hydrolyzing ADP at bite site.

Inhibitor of tissue factor / Factor VIIa complex — blocks extrinsic coagulation pathway.

Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.

Trypsin and Factor Xa inhibitor with broad-spectrum serine protease activity.

Direct thrombin inhibitor from the Asian buffalo leech — hirudin homolog described in Hirudinaria manillensis secretome.

Anticoagulant peptide described in the terrestrial Asian leech Haemadipsa zeylanica.

Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.

Small direct thrombin inhibitor described in the fish leech Piscicola geometra secretome.

Anticoagulant peptide described in the North American medicinal leech Macrobdella decora.

Isoform of saratin — collagen-binding anti-platelet protein from Hirudo medicinalis.

Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.

Isoform of LAPP — collagen-binding inhibitor of platelet adhesion.

Salivary protein blocking platelet adhesion to extracellular matrix components.

Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.

Alternate fibrin-cleaving enzyme reported in Hirudo medicinalis salivary secretions.

Dual-function protease degrading both fibrin clot scaffolds and collagen extracellular matrix.

Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.

Collagen-binding antiplatelet variant from the Hirudo medicinalis sialotranscriptome — paralog of saratin and saratin-2.

Small thrombin-inhibitor peptide identified in the Hirudo medicinalis salivary transcriptome — truncated hirudin-family analog.

Antiplatelet peptide identified in leech salivary transcriptome — inhibits platelet aggregation in vitro.

Paralog of gelin identified in the Hirudo medicinalis sialotranscriptome — putative antiplatelet variant.